You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

CLINICAL TRIALS PROFILE FOR ESZOPICLONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Eszopiclone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00120250 ↗ Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Completed Massachusetts General Hospital Phase 4 2005-06-01 The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
NCT00167375 ↗ Testing the Nocturnal Sleep Latency Profile in Primary Insomnia Completed American Academy of Sleep Medicine 2005-01-01 This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 ↗ Testing the Nocturnal Sleep Latency Profile in Primary Insomnia Completed Sunovion 2005-01-01 This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 ↗ Testing the Nocturnal Sleep Latency Profile in Primary Insomnia Completed University of Pittsburgh 2005-01-01 This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00235508 ↗ Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed Sunovion Phase 4 2005-06-01 To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00247624 ↗ Improving Sleep and Psychological Functioning in People With Depression and Insomnia Completed National Institute of Mental Health (NIMH) Phase 4 2005-10-01 This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.
NCT00247624 ↗ Improving Sleep and Psychological Functioning in People With Depression and Insomnia Completed Philips Healthcare Phase 4 2005-10-01 This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eszopiclone

Condition Name

Condition Name for Eszopiclone
Intervention Trials
Insomnia 27
Obstructive Sleep Apnea 11
Primary Insomnia 10
Sleep Initiation and Maintenance Disorders 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eszopiclone
Intervention Trials
Sleep Initiation and Maintenance Disorders 43
Sleep Apnea, Obstructive 13
Sleep Apnea Syndromes 11
Disease 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eszopiclone

Trials by Country

Trials by Country for Eszopiclone
Location Trials
United States 303
Japan 24
United Kingdom 6
India 3
Ukraine 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eszopiclone
Location Trials
Massachusetts 21
California 18
Pennsylvania 13
Ohio 12
New Jersey 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eszopiclone

Clinical Trial Phase

Clinical Trial Phase for Eszopiclone
Clinical Trial Phase Trials
Phase 4 25
Phase 3 16
Phase 2/Phase 3 2
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eszopiclone
Clinical Trial Phase Trials
Completed 56
Recruiting 6
Not yet recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eszopiclone

Sponsor Name

Sponsor Name for Eszopiclone
Sponsor Trials
Sunovion 35
University of California, San Diego 5
Massachusetts General Hospital 5
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eszopiclone
Sponsor Trials
Other 53
Industry 49
NIH 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.